skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

15 Total results for product and free and sample content found

Medtech Insight

CMS Raises Hospital Reimbursement Rate For Bone Density Scans, But Is It Enough?

By Marion Webb 30 Jan 2017

Advocacy groups for diagnostic services to test for osteoporosis scored a big win when the US Centers for Medicare and Medicaid Services agreed to raise Medicare reimbursement rates for DXA bone density scans in the hospital setting this year rather than cutting the rates as initially proposed.

Topic Reimbursement

RxScorecard

Market Access Article Pack: Value Frameworks

28 Nov 2016

When it comes to value frameworks, one thing is certain, they’re here to stay.

Topic Reimbursement Deal trends

RxScorecard

Maximize your drugs market potential in a payer dominated world

23 Nov 2016

See how the value of drugs differentiate therapies by sub-population. Find out where the disproportionate value of your drug lies alongside competitors. Uncover demonstrable differentiated value when entering a crowded market. Discover the power of RxScorecard™.

Topic Reimbursement

Pink Sheet

Trump’s ACA Repeal: What’s In It For Biopharma?

By Cathy Kelly 15 Nov 2016

Trump’s drive to repeal the Affordable Care Act offers opportunities for biopharma to eliminate the annual drug tax and roll back programs that could enable implementation of US government price controls on drugs without congressional action.

Topic US election Reimbursement

Pink Sheet

Trump’s ACA Repeal: What’s In It For Biopharma?

By Cathy Kelly 15 Nov 2016

Trump’s drive to repeal the Affordable Care Act offers opportunities for biopharma to eliminate the annual drug tax and roll back programs that could enable implementation of US government price controls on drugs without congressional action.

Topic US election Reimbursement

Pink Sheet

Trump’s ACA Repeal: What’s In It For Biopharma?

By Cathy Kelly 15 Nov 2016

Trump’s drive to repeal the Affordable Care Act offers opportunities for biopharma to eliminate the annual drug tax and roll back programs that could enable implementation of US government price controls on drugs without congressional action.

Topic US election Reimbursement

Pink Sheet

Trump’s ACA Repeal: What’s In It For Biopharma?

By Cathy Kelly 15 Nov 2016

Trump’s drive to repeal the Affordable Care Act offers opportunities for biopharma to eliminate the annual drug tax and roll back programs that could enable implementation of US government price controls on drugs without congressional action.

Topic US election Reimbursement

Pink Sheet

Trump’s ACA Repeal: What’s In It For Biopharma?

By Cathy Kelly 15 Nov 2016

Trump’s drive to repeal the Affordable Care Act offers opportunities for biopharma to eliminate the annual drug tax and roll back programs that could enable implementation of US government price controls on drugs without congressional action.

Topic US election Reimbursement

RxScorecard

Market Access Article Pack: Indication-Based Pricing

14 Nov 2016

Indication-based pricing isn’t just coming. It’s here.

Topic Reimbursement

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907

Or email us your inquiry, so we can provide you the best possible customer service:
Pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: